Cell-based cancer vaccine in which a patient's own dendritic cells are loaded with patient-specific neoantigen peptides to present via MHC I/II and prime/expand CD8+ cytotoxic and CD4+ helper T-cell responses.
Autologous dendritic cells are loaded ex vivo with patient-specific neoantigen peptides and reinfused to present these antigens via MHC I/II with costimulatory signals, thereby priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells to mount durable antitumor immune responses.
NO
INDIRECT
The DC vaccine primes neoantigen-specific T cells, which then kill tumor cells presenting the neoantigen peptides on MHC (primarily class I) via perforin/granzyme or Fas–FasL. HLA-DPA1 expression itself is not the target of killing.
Cell-based cancer vaccine in which a patient's own dendritic cells are loaded with patient-specific neoantigen peptides to present via MHC I/II and prime/expand CD8+ cytotoxic and CD4+ helper T-cell responses.
Autologous dendritic cells are loaded ex vivo with patient-specific neoantigen peptides and reinfused to present these antigens via MHC I/II with costimulatory signals, thereby priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells to mount durable antitumor immune responses.
NO
INDIRECT
The DC vaccine primes neoantigen-specific T cells; resulting CD8+ CTLs (and helper CD4+ T cells) kill tumor cells presenting neoantigen peptides, primarily via perforin/granzyme. HLA-DPB1 itself is just an MHC II presenter and is not the killing target.
Cell-based cancer vaccine in which a patient's own dendritic cells are loaded with patient-specific neoantigen peptides to present via MHC I/II and prime/expand CD8+ cytotoxic and CD4+ helper T-cell responses.
Autologous dendritic cells are loaded ex vivo with patient-specific neoantigen peptides and reinfused to present these antigens via MHC I/II with costimulatory signals, thereby priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells to mount durable antitumor immune responses.
NO
INDIRECT
The DC vaccine presents neoantigen peptides with costimulation (CD80/86 engaging CD28) to activate and expand tumor-specific CD8 T cells, which then kill neoantigen-bearing tumor cells via perforin/granzyme or Fas–FasL. CD28+ T cells themselves are not targeted or killed.
Humanized, Fc‑engineered anti‑CD19 monoclonal antibody that binds B cells and enhances ADCC/ADCP and apoptosis.
Fc‑engineered humanized anti‑CD19 monoclonal antibody that binds CD19 on B cells and depletes CD19+ cells by enhancing FcγR‑mediated ADCC and ADCP, with additional direct pro‑apoptotic activity.
YES
DIRECT
Binds CD19 on B cells and engages Fc-gamma receptors to trigger ADCC (e.g., NK cells) and ADCP (macrophages), with additional direct pro-apoptotic signaling in CD19+ cells.
Chimeric anti‑CD20 monoclonal antibody that induces complement-dependent cytotoxicity, ADCC, and apoptosis in B cells.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, resulting in depletion of CD20-positive B cells.
YES
DIRECT
Rituximab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC (and can trigger apoptosis), causing direct killing of CD20+ cells.